Capivasertib (AstraZeneca) is an orally active, highly selective Akt inhibitor that preferentially targets Akt isoforms 1–3. Akt is a key enzyme in the PI3K/Akt/mTOR tumor cell survival pathway and is dysregulated in a number of malignancies through loss of tumor suppressor phosphatase and tensin homolog (PTEN), acquisition of activating mutations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) or AKT1, as well as amplification of PI3K.
Triple-negative breast cancer (TNBC) is associated with activating PI3KCA or AKT1 mutations and alterations in PTEN expression, both of which can lead to activation of the Pl3K/Akt/mTOR pathway. In TNBC, a higher degree of Akt pathway activation has been associated with deficient expression of PTEN.
4 Drug Overview
5 Product Profiles
5 capivasertib : Breast cancer: triple-negative
LIST OF FIGURES
10 Figure 1: Datamonitor Healthcare’s drug assessment summary of capivasertib for TNBC
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of capivasertib for TNBC
LIST OF TABLES
6 Table 1: Capivasertib drug profile
8 Table 2: Late-phase trials of capivasertib for TNBC
9 Table 3: Capivasertib for TNBC – SWOT analysis
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.